Management of genitourinary syndrome of menopause in breast cancer survivors: An update

doi:10.5306/wjco.v13.i2.71

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10760)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

780

WORD

153

HTML

7573

Figures (1-2)

296

Tables (1-5)

378

Sum=9180

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

201

Download

625

Sum=826

Publishing Process of This Article

Item

Count

Browse

234

Download

520

Sum=754

Feb 24, 2022 (publication date) through Jul 24, 2024

Times Cited of This Article

Times Cited (34)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Feb 24, 2022; 13(2): 71-100
Published online Feb 24, 2022. doi: 10.5306/wjco.v13.i2.71

Full Size Figure Download Figure

Figure 1 Treatment of genitourinary syndrome of menopause in women undergoing adjuvant treatment for breast cancer. ¹Dehydroepiandrosterone; ²Prasterone label includes a warning against this use in breast cancer survivors.

Citation: Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: An update. World J Clin Oncol 2022; 13(2): 71-100
URL: https://www.wjgnet.com/2218-4333/full/v13/i2/71.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i2.71